BridgeMD
Tests treatment safety and results for Graves' Disease
Official title A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
ClinicalTrials.gov ID: NCT07018323
What this study is testing
What is IMVT-1402?
IMVT-1402 is an investigational medicine, being studied as a potential treatment for graves' disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol...
- Male or female participants aged ≥ 18 years.
- Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.
- Other, more specific are defined in the protocol.
You likely can't join if
- Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy.
- Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk.
- Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective...
- Additional exclusion criteria are defined in the protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Tucson, Arizona, United States
- Concord, California, United States
- Aurora, Colorado, United States
- Doral, Florida, United States
- Hialeah, Florida, United States
- Miami, Florida, United States
- Columbus, Georgia, United States
- Topeka, Kansas, United States
- Louisville, Kentucky, United States
- Jefferson City, Missouri, United States
- Kansas City, Missouri, United States
- St Louis, Missouri, United States
- Reno, Nevada, United States
- Long Island City, New York, United States
- New Hyde Park, New York, United States
- New York, New York, United States
- Williamsville, New York, United States
- Chapel Hill, North Carolina, United States
- Hickory, North Carolina, United States
- Morehead City, North Carolina, United States
+ 101 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tucson, Arizona, United States; Concord, California, United States; Aurora, Colorado, United States; Doral, Florida, United States; Hialeah, Florida, United States; Miami, Florida, United States and 115 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.